You are here

Sumatriptan-Naproxen Combo Reaches Endpoint in Second Phase 3 Trial

CHAPEL HILL, N.C.--(BUSINESS WIRE)--April 21, 2005--POZEN Inc. (NASDAQ: POZN), announced today that it achieved statistical significance for all regulatory endpoints for Trexima in the second of the two Phase III pivotal trials. Trexima is GlaxoSmithKline's (GSK) proposed brand name for the combination of sumatriptan formulated with RT Technology(TM) and naproxen sodium in a single tablet. GSK and POZEN are collaborating on the development of Trexima.

POZEN also announced that it has met with the FDA and discussed the results of both Phase III trials and other information required for the submission of the Trexima NDA. Based upon discussions at the pre-NDA meeting, POZEN believes that no additional pre-clinical or clinical trials are necessary for submission. The Trexima NDA submission is now scheduled for the third quarter of 2005.

In the second Phase III study, Trexima demonstrated superiority over the individual components on the primary endpoint and also met all the regulatory endpoints for a new migraine product. For the combination, Trexima demonstrated a superior sustained pain-free response versus naproxen (p "We are obviously very pleased with the pre-NDA meeting resulting in our ability to submit the Trexima NDA early in the second half of this year," said Dr. John R. Plachetka, Chairman, President and CEO. "The team has done a remarkable job in completing the two pivotal studies in less than a year from start to finish."

Source: Pozen and GlaxoSmithKline

Recent Headlines

Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Vitamin E Found in Samples Around the Country
Study Links Them to Premature Death
Nag With Texting and a ‘Winners Circle’
How Serotonin and Fluoxetine Affect Microbiota Residing in the Gut